![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: JADE3 |
Gene summary for JADE3 |
![]() |
Gene information | Species | Human | Gene symbol | JADE3 | Gene ID | 9767 |
Gene name | jade family PHD finger 3 | |
Gene Alias | JADE-3 | |
Cytomap | Xp11.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R1A2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9767 | JADE3 | HCC1_Meng | Human | Liver | HCC | 2.11e-14 | 2.56e-02 | 0.0246 |
9767 | JADE3 | HCC1 | Human | Liver | HCC | 4.54e-29 | 5.51e+00 | 0.5336 |
9767 | JADE3 | HCC2 | Human | Liver | HCC | 4.36e-05 | 3.21e+00 | 0.5341 |
9767 | JADE3 | S016 | Human | Liver | HCC | 6.26e-04 | 1.95e-01 | 0.2243 |
9767 | JADE3 | S028 | Human | Liver | HCC | 1.33e-05 | 2.79e-01 | 0.2503 |
9767 | JADE3 | S029 | Human | Liver | HCC | 3.79e-05 | 3.23e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:00439671 | Liver | HCC | histone H4 acetylation | 50/7958 | 67/18723 | 9.14e-08 | 1.82e-06 | 50 |
GO:0043966 | Liver | HCC | histone H3 acetylation | 37/7958 | 61/18723 | 3.21e-03 | 1.48e-02 | 37 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
JADE3 | SNV | Missense_Mutation | rs782728369 | c.1811N>A | p.Arg604His | p.R604H | Q92613 | protein_coding | tolerated_low_confidence(0.08) | benign(0.118) | TCGA-AP-A05H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
JADE3 | SNV | Missense_Mutation | c.2030N>C | p.Val677Ala | p.V677A | Q92613 | protein_coding | tolerated_low_confidence(0.21) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
JADE3 | SNV | Missense_Mutation | novel | c.1313N>A | p.Arg438Gln | p.R438Q | Q92613 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
JADE3 | SNV | Missense_Mutation | novel | c.2122N>G | p.Thr708Ala | p.T708A | Q92613 | protein_coding | tolerated_low_confidence(0.68) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
JADE3 | SNV | Missense_Mutation | novel | c.1221N>A | p.Phe407Leu | p.F407L | Q92613 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
JADE3 | SNV | Missense_Mutation | rs782548118 | c.956N>T | p.Thr319Met | p.T319M | Q92613 | protein_coding | tolerated(0.06) | possibly_damaging(0.701) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
JADE3 | SNV | Missense_Mutation | c.2104N>A | p.Gly702Ser | p.G702S | Q92613 | protein_coding | tolerated_low_confidence(0.68) | benign(0) | TCGA-B5-A0JR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
JADE3 | SNV | Missense_Mutation | c.1063N>A | p.Glu355Lys | p.E355K | Q92613 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
JADE3 | SNV | Missense_Mutation | novel | c.114N>T | p.Lys38Asn | p.K38N | Q92613 | protein_coding | deleterious(0.04) | benign(0.299) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
JADE3 | SNV | Missense_Mutation | novel | c.1392N>G | p.Ser464Arg | p.S464R | Q92613 | protein_coding | tolerated(0.1) | possibly_damaging(0.791) | TCGA-BS-A0UT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |